Baltimore, MD, Feb. 21, 2026 (GLOBE NEWSWIRE) -- Jim Rickards is being recognized by Paradigm Press for his forecasting record after a series of high-impact political, financial, and macro developments unfolded in line with projections he outlined in advance. The designation from Paradigm Press reflects his work analyzing structural changes tied to government policy, global power shifts, and financial systems—an approach that has defined his research for decades and continues to shape his latest national br ...

Group 1 - Choice Hotels International, Inc. experienced a data breach in January 2026, potentially compromising personal information of individuals, including names, Social Security numbers, and dates of birth [2][3] - Wolf Haldenstein Adler Freeman & Herz LLP is investigating claims on behalf of those affected by the data breach [1] - Affected individuals have been notified that their personal information may be for sale on the dark web [3] Group 2 - Wolf Haldenstein is recognized for its expertise in consumer rights litigation across various courts in the United States [5] - The firm has multiple offices in major cities, including New York, Chicago, Nashville, and San Diego [5] - The firm is actively seeking to assist individuals impacted by the data breach and has provided contact information for inquiries [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of PomDoctor Ltd. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class period for the PomDoctor securities is from October 9, 2025, to December 11, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 7, 2026 [2] Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [3] - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3] Group 3: Case Allegations - The lawsuit alleges that PomDoctor was involved in a fraudulent stock promotion scheme that included misinformation on social media and impersonation of financial professionals [4] - It is claimed that insiders used offshore accounts to facilitate the dumping of shares during a price inflation campaign [4] - The public statements and risk disclosures from PomDoctor allegedly omitted critical information regarding false rumors and artificial trading activity affecting the stock price [4]

Core Viewpoint - AnorTech Inc. has granted incentive stock options to directors, employees, and consultants, allowing the purchase of a total of 5,150,000 shares at a price of $0.10 per share [1] Summary by Category Stock Options - The total number of shares for the stock options granted is 5,150,000 [1] - The exercise price for the options is set at $0.10 per share [1] - The options will vest over a period of 18 months and have a term of five years [1] Regulatory Compliance - The stock options are subject to the policies of the TSX Venture Exchange [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased agilon health, inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought agilon securities between February 26, 2025, and August 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 2, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Agilon - The lawsuit alleges that during the Class Period, defendants made false and misleading statements and failed to disclose critical information, including: 1. Reckless issuance of guidance for 2025 that was unlikely to be achieved due to known industry challenges 2. Material overstatement of the financial impact from strategic actions taken by agilon to mitigate risk 3. Overall misleading statements regarding agilon's business, operations, and prospects [5].

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. and its executives due to significant stock drop linked to potential violations of federal securities laws [1][3]. Company Overview - Fermi Inc. is an energy and AI infrastructure company aiming to build large-scale nuclear reactors to support grid-independent data centers for AI companies [4]. - The company's flagship project is Project Matador, designed to provide dedicated power for AI workloads [4]. IPO and Allegations - Fermi completed its IPO in October 2025, claiming strong demand for Project Matador and securing a 20-year lease with an investment-grade-rated tenant [5]. - Allegations suggest that Fermi overstated tenant demand and misrepresented the agreement with the First Tenant [6]. Stock Performance - Following the announcement of the First Tenant's termination of the Advance in Aid of Construction Agreement on December 11, 2025, Fermi's stock dropped by $5.16, or over 33%, from $15.25 to $10.09 per share [7].

Core Viewpoint - A class action lawsuit has been filed against Plug Power Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of New York, titled Ortolani v. Plug Power Inc., et al., No. 1:26-cv-00165 [3]. - Investors have until April 3, 2026, to request to be appointed to lead the case, with claims asserted under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Company Background - Plug Power specializes in hydrogen fuel cell turnkey solutions for electric mobility and stationary power markets, and develops infrastructure such as hydrogen production plants [4]. - The company announced a "closed a $1.66 billion loan guarantee" from the U.S. Department of Energy to finance the construction of hydrogen production facilities [4]. Group 3: Stock Performance and Events - On October 7, 2025, Plug Power's stock dropped by $0.26 per share (6.3%) following the abrupt departure of CEO Andrew Marsh and President Sanjay Shrestha, from $4.13 to $3.87 per share [5]. - On November 10, 2025, the company announced the suspension of activities under the DOE loan program, leading to a stock drop of $0.09 per share (3.4%), from $2.65 to $2.56 per share [6]. - A report on November 13, 2025, confirmed the suspension of plans to construct hydrogen production facilities, resulting in a stock drop of $0.48 per share (17.6%), from $2.49 to $2.25 per share [7].

Core Viewpoint - A class action lawsuit has been filed against BellRing Brands, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Denha v. BellRing Brands, Inc., No. 1:26-cv-00575 [2]. - Investors have until March 23, 2026, to request to be appointed to lead the case [2]. Group 2: Company Background - BellRing Brands develops, markets, and sells "convenient nutrition" products, primarily ready-to-drink protein shakes under the Premier Protein brand [3]. - The company previously claimed that its sales growth was due to increased consumer demand and various positive factors, while downplaying competitive pressures [3]. Group 3: Stock Performance and Impact - On May 6, 2025, BellRing's CFO indicated that several key retailers had reduced their inventory levels, leading to a projected mid-single-digit headwind for Q3 growth, resulting in a stock price drop of $14.88 per share, or 19% [4]. - Following the Q3 2025 financial results reported on August 4, 2025, which included a narrowed fiscal year outlook, the stock dropped by $17.46 per share, nearly 33%, from $53.64 to $36.18 [5][6].

Core Viewpoint - A class action lawsuit has been filed against Kyndryl Holdings, Inc. and certain senior executives for securities fraud following significant stock drops due to potential violations of federal securities laws [1][3]. Group 1: Company Overview - Kyndryl is a provider of enterprise technology services, offering advisory, implementation, and managed service capabilities to customers in over 60 countries, making it the world's largest IT infrastructure services provider [4]. Group 2: Allegations and Stock Impact - Kyndryl is accused of misrepresenting its cash management practices, including the drivers of its adjusted free cash flow metric and the effectiveness of its internal controls over financial reporting for FY2025 and the first three quarters of FY2026 [5]. - On February 9, 2026, Kyndryl announced a delay in releasing its fiscal Q3 2026 financial statement due to an accounting review of its cash management practices, leading to the immediate departures of its CFO and General Counsel [6]. - Following this announcement, Kyndryl's stock price dropped over 52% during trading on February 9, 2026 [7].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections" while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health disclosed a $43 million revenue decrease for the quarter and increased professional liability reserves by $54 million, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].